Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Expanding indications for neuromodulation.

Andrew J Bernstein1, Kenneth M Peters

  • 1Department of Urology, William Beaumont Hospital, 3535 West 13 Mile Road, Suite 438, Royal Oak, MI 48073, USA.

The Urologic Clinics of North America
|February 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical phenotypes and treatment patterns in men with chronic pelvic pain: a tertiary referral cohort.

International urology and nephrology·2026
Same author

Editorial Comment.

The Journal of urology·2026
Same author

Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.

Neurourology and urodynamics·2025
Same author

Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments.

Obstetrical & gynecological survey·2025
Same author

Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.

Current opinion in urology·2025
Same author

Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.

Urology·2025
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Neuromodulation offers a durable and effective therapy for various conditions, improving quality of life. This minimally invasive approach is becoming a first-line treatment, potentially replacing surgery for voiding dysfunctions and other chronic disorders.

Area of Science:

  • Neurology
  • Urology
  • Bioelectronic Medicine

Background:

  • Neuromodulation has a long history of study for diverse diseases.
  • While mechanisms are unclear, clinical successes demonstrate efficacy and durability.
  • Approved applications include sacral neuromodulation for urinary dysfunction.

Purpose of the Study:

  • To explore the expanding applications and future potential of neuromodulation.
  • To highlight neuromodulation as a minimally invasive alternative to traditional treatments.
  • To position neuromodulation as a potential first-line therapy in urology and beyond.

Main Methods:

  • Review of existing clinical studies and applications of neuromodulation.
  • Discussion of current and potential future therapeutic targets.

Related Experiment Videos

  • Analysis of neuromodulation's impact on quality of life.

    • Main Results:

    • Neuromodulation is effective for urinary urgency, frequency, retention, and urge incontinence.
    • Promising applications include interstitial cystitis, pain syndromes, fecal incontinence, constipation, spinal cord injury, and erectile dysfunction.
    • Neuromodulation improves quality of life in adults and children with chronic conditions.

    Conclusions:

    • Neuromodulation is transforming urology, offering a minimally invasive treatment for voiding dysfunction and pelvic disorders.
    • It presents a viable alternative to medications and complex surgeries.
    • Neuromodulation is poised to become a primary therapeutic option before surgical intervention.